2024 MIIF China: Bridging the present and future of laboratory diagnostics

2024 MIIF China: Bridging the present and future of laboratory diagnostics

First held in 2011, MIIF brings together more than a thousand laboratory experts from more than a hundred countries to exchange the latest knowledge and best practices in laboratory diagnostics. This year, at 2024 MIIF China, co-organized by IFCC, EFLM, SIBioC and Mindray on April 23-24, more than two hundred laboratory professionals from all over the world gathered to discuss the latest progress and future of this field. trend. Covering a variety of topics from novel biomarkers to cutting-edge diagnostic technologies, the forum provides insights into the future prospects of the industry through insightful discussions.

At the opening ceremony, Mr. Li Zaiwen, Senior Vice President of Mindray, delivered a speech, emphasizing the importance of exchanges and cooperation among global laboratory professionals in promoting the advancement of laboratory medicine.

The academic forum was exciting, with experts from industry associations such as IFCC, EFLM, SIBioC and well-known universities expressing their opinions and latest research results on various topics. These topics include novel cardiac biomarkers, digital morphology, and laboratory development and certification.

In a roundtable discussion with the theme of "Innovation in the Heart", experts discussed the clinical value of cardiac biomarkers such as high-sensitivity troponin I and the future prospects of new cardiac marker research. Dr. He Jianwen, Chief Scientist of Mindray In Vitro Diagnostics, emphasized Mindray's close integration with the clinical environment, rigorous verification of clinical applications, and continuous innovation to meet growing needs. The recently launched high-sensitivity troponin I has been recognized by the world's top experts, demonstrating Mindray's latest achievements in addressing the clinical challenges of cardiovascular disease.

Novel serum solutions for mid-sized laboratories
At the meeting, Mindray also held a grand launch conference of a new serum solution designed specifically for medium-sized laboratories, including two independent analyzers (CL-2600i and BS-1000M) and two integrated solutions (M680 and M980). With their compact design and high efficiency, these new products demonstrate Mindray's continued commitment to technological innovation in chemiluminescent immunoassays and clinical chemistry.

The successful conclusion of MIIF China in 2024 is not the end of a chapter, but the beginning of a grand journey to jointly achieve the goal of "Lab Vision 2030". Mindray remains steadfast in partnering with laboratory professionals around the world to shape a brighter future and enhance patient care for all.